Table 1_The advanced lung cancer inflammation index as a predictor of kidney stone risk in men: a cross-sectional analysis.docx by Yan Zhou (6523)

“…Background<p>Kidney stone incidence and recurrence are increasing, which poses significant health problems. The Advanced Lung Cancer Inflammation Index (ALI) combines body mass index (BMI), albumin, and neutrophil-to-lymphocyte ratio (NLR). …”

<b>Data used for analyses in the manuscript 'Sleep Regularity and Duration are Associated with Depression Severity in a Nationally Representative United States Sample'</b> by Katherine Maki (7445153)

Table 4_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…</p>Results<p>Testing revealed distinct genomic profiles of lung adenocarcinoma and squamous cell carcinomas and detected variants with a current targeted therapy or clinical trial in >72% of patient tumors. Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Table 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…</p>Results<p>Testing revealed distinct genomic profiles of lung adenocarcinoma and squamous cell carcinomas and detected variants with a current targeted therapy or clinical trial in >72% of patient tumors. Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Table 5_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…</p>Results<p>Testing revealed distinct genomic profiles of lung adenocarcinoma and squamous cell carcinomas and detected variants with a current targeted therapy or clinical trial in >72% of patient tumors. Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Table 2_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…</p>Results<p>Testing revealed distinct genomic profiles of lung adenocarcinoma and squamous cell carcinomas and detected variants with a current targeted therapy or clinical trial in >72% of patient tumors. Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Table 3_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…</p>Results<p>Testing revealed distinct genomic profiles of lung adenocarcinoma and squamous cell carcinomas and detected variants with a current targeted therapy or clinical trial in >72% of patient tumors. Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Data Sheet 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and... by Zachary D. Wallen (19986522)

“…</p>Results<p>Testing revealed distinct genomic profiles of lung adenocarcinoma and squamous cell carcinomas and detected variants with a current targeted therapy or clinical trial in >72% of patient tumors. Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Table_1_Association between serum iron levels and atherosclerotic cardiovascular diseases among American older adults: a cross-sectional study based on the National Health and Nutr... by Xiaochen Yu (3796927)

Table_3_Association between tea consumption and stroke in the American adult females: analyses of NHANES 2011–2018 data.XLSX by Yongyue Miao (19925808)

Table_2_Association between tea consumption and stroke in the American adult females: analyses of NHANES 2011–2018 data.xlsx by Yongyue Miao (19925808)

Data_Sheet_1_Association between tea consumption and stroke in the American adult females: analyses of NHANES 2011–2018 data.zip by Yongyue Miao (19925808)

Table_1_Association between tea consumption and stroke in the American adult females: analyses of NHANES 2011–2018 data.docx by Yongyue Miao (19925808)

Image_1_Dietary soy protein reverses obesity-induced liver steatosis and alters fecal microbial composition independent of isoflavone level.JPEG by Reza Hakkak (11086)

Table_1_Dietary soy protein reverses obesity-induced liver steatosis and alters fecal microbial composition independent of isoflavone level.DOCX by Reza Hakkak (11086)

Image_3_RETRACTED: Ammonia Scavenger Restores Liver and Muscle Injury in a Mouse Model of Non-alcoholic Steatohepatitis With Sarcopenic Obesity.TIF by Zi-Xuan Wang (134651)

Image_4_RETRACTED: Ammonia Scavenger Restores Liver and Muscle Injury in a Mouse Model of Non-alcoholic Steatohepatitis With Sarcopenic Obesity.TIF by Zi-Xuan Wang (134651)

Image_1_RETRACTED: Ammonia Scavenger Restores Liver and Muscle Injury in a Mouse Model of Non-alcoholic Steatohepatitis With Sarcopenic Obesity.TIF by Zi-Xuan Wang (134651)

Image_2_RETRACTED: Ammonia Scavenger Restores Liver and Muscle Injury in a Mouse Model of Non-alcoholic Steatohepatitis With Sarcopenic Obesity.TIF by Zi-Xuan Wang (134651)

Study group background characteristics. by Zicheng Hu (3825313)

“…Other intergroup comparisons were not significant. Overall, the albumin ratio elevations were small, and likely to have had only limited, if any, impact on the CSF proteins measured in this panel. …”